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Abstract 
Objective: To determine whether rheumatoid factor (RF), anti-CCP antibodies, or carriage of 
shared epitope (SE) and PTPN22 genetic susceptibility variants predict response to anti-TNF 
therapy in a large cohort of patients with rheumatoid arthritis (RA). 
Methods: UK-wide multi-centre collaborations were established to recruit a large cohort of 
patients treated with anti-TNF drugs for RA. Serum RF, anti-CCP antibody and SE status were 
determined using commercially available kits. In addition, PTPN22 R620W genotyping was 
performed using a Sequenom MassArray® platform. Linear regression analyses were performed 
to investigate the role of these 4 factors in predicting response to treatment by 6 months, defined 
as the absolute change in DAS28. Any effects observed across the entire cohort were explored 
further to determine whether these factors were better predictors of response to one or other of 
the anti-TNF agents. 
Results: Of the 642 patients analysed, 46% received infliximab, 43% etanercept and 11% 
adalimumab. Eighty nine per cent were RF positive and 82% were anti-CCP positive. The mean 
baseline DAS28 was 6.7 and by 6-months had improved by a mean of 2.5 units. Patients who 
tested negative for RF had a 0.49 (95% CI 0.1, 0.9) greater mean improvement in DAS28 
compared to RF positive patients. A better response was also seen among patients who tested 
negative for anti-CCP. Upon stratification, the association of both RF and anti-CCP antibody 
status was restricted to the infliximab treatment group. No association was demonstrated 
between drug response and SE or PTPN22 620W carriage, under any model. 
Conclusion: The presence of RF or anti-CCP antibodies was associated with a reduced response 
to anti-TNF drugs as a whole and infliximab, in particular. However, these antibodies only 
account for a small proportion of the variance in treatment response. It is likely that genetic 
factors will contribute to the response to treatment but these do not include the 2 genes known to 
confer susceptibility to RA. 
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Introduction 
The identification of the key role played by tumour necrosis factor (TNF) in the pathogenesis of 
rheumatoid arthritis (RA) resulted in the development of new therapies that target and block the 
action of this cytokine. Consequently, 3 such anti-TNF biologic agents have been approved to 
date, namely etanercept (Enbrel; Amgen/Wyeth), infliximab (Remicade; Centocor/Johnson & 
Johnson/Schering-Plough) and more recently adalimumab (Humira; Abbott) (1). Collectively 
these drugs have become one of the most effective methods of treating RA, with nearly half of 
all treated patients achieving an American College of Rheumatology 20% (ACR20) 
improvement level or higher. Furthermore, in addition to reducing disease activity, these agents 
have been reported to inhibit radiological progression (2).  
 
However, there is still a substantial proportion of patients who show partial or no response to 
anti-TNF therapy. As treatment with such biologic agents is limited by expensive annual costs in 
many countries, there is a clinical need to identify methods of prospectively determining those 
patients most, or indeed least, likely to benefit. 
 
A number of demographic and disease specific factors have been examined, but few predictors 
of response have been consistently identified (3-5). In particular, analyses in a large scale 
longitudinal observational study cohort identified higher baseline health assessment 
questionnaire (HAQ) scores and current smoking status as predictors of lower response rates, 
although this latter factor was only significant in the group of patients treated with infliximab 
(5). Age, disease duration and number of previous disease modifying anti-rheumatic drugs 
(DMARDs) did not predict response to either infliximab or etanercept. Several smaller studies 
(sample sizes < 130) have also investigated the utility of auto-antibodies, including rheumatoid 
 4
factor (RF) and anti-cyclic citrullinated peptide (anti-CCP), for predicting response to treatment 
with a biologic agent but results have been inconsistent (3;4;6;7).  
 
Genetic factors are also likely to play a key role in determining treatment response. Although 
previous studies have had limited success in identifying genetic predictors, most of these studies 
were hindered by small sample sizes resulting in limited power to detect modest effects. For 
instance, association of the TNF gene promoter polymorphism at position -308 with response to 
infliximab was reported in 4 small European populations (n<90) (8-11), but was not replicated in 
a larger cohort of 198 French patients with RA (12). Similarly, a significant association was 
demonstrated between carriage of the shared epitope (SE) and response to etanercept in a large 
cohort of 200 US patients (13) but was not replicated in a smaller cohort of 123 Swedish patients 
(14). Furthermore, no association of SE status with response to infliximab treatment was 
observed in two European populations (n= 78 Spanish and 198 French patients, respectively) 
(12;15). Whether this latter difference could be explained by varying pharmacokinetics/dynamics 
between the two drugs remains to be determined. Additional studies have investigated 
polymorphisms in the genes encoding IL1β  and the IL1-receptor antagonist (12;14), IL10 
(14;16), TGFβ1 (14) and FcγRIIIA (17;18), but few have identified consistent associations with 
response to anti-TNF treatment response.  
 
Thus, in order to aid the identification of genetic predictors of response, we established a UK-
wide multi-centre collaboration to recruit a large cohort of patients treated with anti-TNF 
biologic therapies for RA. Here we present analyses investigating the role of RF status, anti-CCP 
status, and carriage of the SE in determining response to treatment. Carriage of the 
PTPN22*620W variant, a now well-established RA susceptibility factor, was also investigated. 
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Methods 
Study design 
Anti-TNF (etanercept, infliximab, adalimumab) treated patients were recruited from 
rheumatology centres throughout the UK. In a subset for which DNA had been extracted, a 
within-cohort association study was performed to investigate the role of RF, anti-CCP 
antibodies, SE carriage and PTPN22*620Wcarriage in predicting response to treatment at 6 
months. Interaction analyses were also performed to determine whether any effects observed 
were better predictors for one or other of the anti-TNF drugs. 
 
Patient selection – UK-wide multi-centre collaborations were established to recruit a large 
cohort of patients treated with anti-TNF drugs for RA. Eligible patients from each centre were 
subsequently identified from the British Society of Rheumatology’s (BSR) Biologics Register 
(BR) (19). This register compiles extensive clinical information on patients starting treatment 
with a biologic agent and follows them prospectively, on a 6-monthly basis for 5 years, in order 
to monitor and determine the incidence of potential short and long term hazards. The following 
criteria were used for the selection of patients: 1) currently actively participating in the BSRBR 
long-term safety study, 2) physician-confirmed diagnosis of RA, 3) currently or have been 
treated with one of the 3 anti-TNF biologic agents, 4) European Caucasian descent and 5) 
reached 6 months of follow-up. Patients who stopped treatment temporarily during the first 6 
months of therapy were excluded from selection. Similarly, patients who discontinued therapy 
prior to the 6 month follow-up for any reason other than inefficacy were excluded from 
selection. 
 
Patient recruitment and sample collection – Patients from each collaborating centre were 
identified from the BSRBR and, through an initial mailing, invited to take part in the study by 
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the relevant consultants. Additional blood samples were obtained from consenting patients when 
they attended local rheumatology clinics for blood tests required as part of routine care. The 
additional blood samples and signed consent forms were subsequently posted back to the 
Arthritis Research Campaign (arc) unit at the University of Manchester for processing and 
storage. For the majority of patients two samples of blood were taken, one plain and one EDTA 
tube, from which serum and DNA could be extracted, respectively. DNA was isolated using a 
standard phenol/chloroform extraction method. Both serum and DNA samples were stored at -
80°C. 
 
UK Central Office of Research Ethics Committees (COREC) approval (04/Q1403/37) was 
obtained for the collection of DNA and serum samples from patients receiving anti-TNF therapy 
for the treatment of RA.  
 
Clinical information - Clinical data held on the BRSBR database was extracted, with the 
consultants’ permission, and compiled for each consenting patient and included: gender, date of 
birth, year of disease onset, details of the American College of Rheumatology (ACR) 
classification criteria for RA (20), smoking status, Health Assessment Questionnaire (HAQ) 
score (21), details of biologic and non-biologic anti-rheumatic drug therapy (including drug type, 
changes to therapy, reasons for discontinuation and previous biologic therapy). Disease activity, 
measured using the 28-joint count disease activity score (DAS28) was extracted at baseline and 
at 6-months follow-up (22). 
 
Immunogenetics – Serum RF and anti-CCP antibody titre were measured using commercially 
available kits (RF-PAIA Immunoturbidimetric Assay for rheumatoid factor, Diastat™ Anti-CCP 
Kit (Axis-Shield Diagnostics Limited, UK)). Patients with titres greater than or equal to 
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40units/ul and 5units/ul were defined as positive for RF and anti-CCP antibodies, respectively. 
HLA-DRB1 typing was performed using commercially available kits (Dynal RELI™ SSO HLA-
DRB1 Typing Kit (Dynal Biotech Limited, UK)). The SE was defined as the presence of any of 
the following alleles: HLA-DRB1*0101, *0102, *0104, *0401, *0404, *0405, *0408 or *1001. 
In addition, PTPN22 R620W (1858C/T) genotyping was performed using MassARRAY® 
iPLEX™ assays, followed by matrix-assisted laser desorption/ionisation time of flight (MALDI-
TOF) mass spectrometry (MS) (Sequenom, Cambridge, UK). Assays were designed and 
performed as recommended by the manufacture (PCR primer 1: 
ACGTTGGATGACTGAACTGTACTCACCAGC, PCR primer 2: 
ACGTTGGATGAGATGATGAAATCCCCCCTC, iPLEX extension primer 
CCCCTCCACTTCCTGTA, extension direction: R).  
 
Analysis 
The primary outcome measure was change in DAS28 between baseline and 6-months. Linear 
regression analyses were performed to investigate association between change in DAS28 and the 
4 factors under investigation; namely, RF and anti-CCP status, SE and PTPN22*620W carriage. 
For the purposes of this analysis, the recorded 6 month DAS28 score was used whether patients 
had discontinued therapy or not. Analyses were adjusted for baseline DAS28, baseline HAQ 
score, administration of concurrent DMARDs and gender, as these factors have previously been 
shown to be significant independent predictors of response (5). Analyses were repeated 
excluding any patients with previous exposure to a biologic drug, whether or not it was the same 
agent. In addition, interaction analyses were performed to determine whether any observed 
effects were similar across the two major drug types, namely etanercept and infliximab. Patients 
treated with adalimumab were excluded from this latter analysis due to the small numbers in this 
subgroup. 
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Results 
Patient recruitment 
Collaborations were established with 20 rheumatology centres across the UK from which 1,485 
patients receiving anti-TNF therapy for RA were eligible for recruitment based on the criteria 
outlined. Of these patients, 1,292 responded to the invitation letter (87%) with 1,195 patients 
willing to take part (80%). DNA samples were extracted and available for the first set of 642 
patients to be recruited, which were utilized in the current analysis. 
 
Baseline characteristics and immunogenetics 
Baseline characteristics for the group of 642 patients are presented in Table 1. Across this group; 
296 patients had received infliximab (46%), 278 etanercept (43%) and 68 adalimumab (11%). 
The proportion of females, mean age, disease duration, baseline DAS28 and HAQ scores were 
comparable across all drug types. In addition, these measures were comparable to previous data 
reported on the BSRBR as a whole (23). A smaller proportion of patients receiving adalimumab 
were current or previous smokers compared to those receiving either etanercept or infliximab. 
Across the combined cohort, 41% and 73% of patients were receiving concurrent steroids and 
single/combined DMARD therapy, respectively. A substantially greater proportion of patients 
receiving infliximab were receiving concurrent DMARD therapy, compared to those being 
treated with either etanercept or adalimumab. Finally, a small proportion of patients were 
recorded as having previous exposure to a biologic agent (5%). 
 
Genotyping of the PTPN22 R620W (C1858T) polymorphism was successfully performed in 
96% of the samples, with 30% being carriers of the minor T risk allele (Table 2). Of those that 
were successfully typed at the HLA-DRB1 locus, 81% were defined as SE positive (Table 2). In 
 9
addition, for subjects for whom serum samples were available, 89% and 82% were positive for 
RF and anti-CCP antibodies, respectively (Table 2). 
 
Predictors of response  
By the first 6 months follow-up, 90% of this group of patients were still receiving anti-TNF 
therapy. The remaining 10% had discontinued treatment due to inefficacy. In total, 21% of 
patients were non-responders, 52% moderate responders and 27% good responders, based on the 
European League Against Rheumatism (EULAR) improvement criteria (24). The mean change 
in DAS28 was an improvement of 2.5 points. Both baseline and absolute change in DAS28 
values were normally distributed across the patient population.  
 
Regression analyses were first performed to investigate association between drug response and 
baseline factors including concurrent DMARD therapy, HAQ score, disease duration and gender. 
Concurrent DMARD therapy and baseline HAQ score were strongly associated with drug 
response. Specifically, patients on concurrent DMARD therapy demonstrated a significantly 
greater improvement compared to those without (Coef: 0.50, 95% CI: 0.24, 0.76, p=1.5x10-4), 
whereas higher baseline HAQ scores were significantly associated with smaller improvements 
(Coef: -0.48, 95% CI: -0.70, -0.26, p=1.8x10-5). In addition, females demonstrated a reduced 
improvement compared to males (Coef: -0.40, 95% CI: -0.68, -0.11, p = 6.2x10-3). Baseline age 
and disease duration, smoking status and concurrent steroid therapy were not associated with 
drug response at 6 months (p>0.05). These findings were expected as associations to the former 
three factors have been previously reported in the BSR Biologics register, from which the current 
cohort was recruited (5).  
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Thus, regression analyses were performed to investigate association of drug response with RF, 
anti-CCP, SE and PTPN22 R620W status, adjusting for baseline DAS28, concurrent DMARD 
therapy, baseline HAQ score and gender (Tables 3). Compared to patients negative for RF, RF-
positive patients demonstrated significantly less improvement in their DAS28 values following 
anti-TNF therapy (Coef: -0.48, 95% CI: -0.87, -0.08, p=0.018) (Table 3). Similarly, patients 
positive for anti-CCP antibodies demonstrated significantly less improvement in DAS28 
compared to anti-CCP negative subjects (Coef: -0.39, 95% CI: -0.71, -0.07, p=0.017) (Table 3). 
Repeating the analysis after exclusion of patients with a previous exposure to a biologic agent 
did not alter these conclusions (Table 3). 
 
No association was demonstrated between drug response and either SE or PTPN22*620W 
carriage, under any model tested (p>0.05) (Table 3). 
 
The effects of RF and anti-CCP antibodies were investigated further by performing multivariate 
linear regression combining both antibodies. Being positive for both RF and anti-CCP did not 
better predict response to anti-TNF therapy (RF only: R2 = 0.17, anti-CCP only: R2 = 0.17, RF 
plus anti-CCP: R2 = 0.17). Furthermore, there was no interaction between these two factors and 
their association with drug response (RF*anti-CCP: R2 = 0.18, p = 0.16). However, as a small 
proportion of patients were positive for only one antibody, these analyses may be underpowered.  
 
Finally, in order to investigate whether the predictive effects of RF and anti-CCP antibodies were 
equal for both etanercept and infliximab response, linear regression was performed including the 
interaction between drug type and autoantibody status. These analyses suggested that, although 
the effects of both RF and anti-CCP antibodies appeared restricted to infliximab-treated patients, 
the difference was not statistically different across the two major drug types (Table 4). However, 
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we had access to serum, but not DNA, samples from a further 240 patients (130 etanercept- and 
110 infliximab- treated). When these were included in the analyses, we found that RF, but not 
anti-CCP, was a significantly greater predictor of response in infliximab rather than etanercept 
treated patients (difference between drugs- Coef: -0.71, 95% CI: -1.4, -0.02 p=0.05). 
 
Discussion 
 
In the largest such study to date, we have attempted to identify genetic and serological predictors 
of biologic treatment response. In keeping with previous reports, we have shown that the 
presence of RF and anti-CCP antibodies is associated with a reduced improvement in the DAS28 
score at 6 months, particularly in infliximab-treated patients. No associations were demonstrated 
between drug response and carriage of risk alleles for either of the 2 known RA susceptibility 
genes, SE or PTPN22*620W. 
 
The introduction of anti-TNF biologic agents has transformed the management of RA. However, 
a substantial proportion of patients still demonstrate partial or no response and there remains a 
clinical need to develop methods of identifying patients who are more (or less) likely to benefit 
from such treatments. Predictors of response may include clinical, psychological, serological and 
genetic factors. Whilst this exploration is still in its infancy, previous studies have suggested that 
the effect of clinical factors alone is relatively modest (3-5). Hence, in the current study, we have 
focussed on genetic and serological markers.  
 
There are a number of methodological limitations to the study, which require discussion. Firstly, 
although the current analyses may inform predictions of how patients receiving anti-TNF 
therapies will respond to those treatments, the lack of a control group of non-anti-TNF treated 
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RA patients means that the study cannot inform the debate about whether a patient will respond 
better to therapy with an anti-TNF rather than a DMARD treatment. 
 
Secondly, response measures were assessed at 6 rather than 3 months, when clinical decisions 
regarding the continuation of therapy are usually made. Consequently, ~10% of patients had 
discontinued therapy due to inefficacy prior to the 6 month follow-up and some will have 
commenced alternative treatment to which they may have responded. Hence, the DAS28 at 6 
months may not be a true reflection of the DAS28 when the drug was discontinued. However, 
this group of patients generally remained non-responders at 6 months despite possibly receiving 
alternative drugs (mean DAS28 improvement at 6 months: 0.8 compared to 2.7 across remaining 
cohort). As the study aims to identify predictors of response by 6 months rather than predictors 
of response only in those who remain on treatment, these patients were included in the analysis 
although we recognise that this may have resulted in underestimations of observed effects. 
 
Thirdly, as one of the requirements for prescribing anti-TNF agents in the UK includes failure of 
at least 2 previous DMARDs, the patients recruited have long-standing RA with a mean duration 
of 14 years. As discussed by Hyrich et al, assessing disease activity in such a group can be 
problematic as current joint swelling and tenderness may be a consequence of structural and 
irreversible damage caused by previous active disease and not current disease activity (5). 
Hence, patients with more severe disease as a result of irreversible joint damage may be less 
likely to respond to treatment. In order to account for this, analyses were repeated adjusting for 
disease duration, but this did not change the overall conclusions of the study (data not shown). 
However, as the anti-TNF agents become more commonly prescribed earlier in the disease 
course, it may be necessary to repeat these analyses.  
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Fourthly, small numbers of samples exist in some subgroups. In particular, as adalimumab was 
the most recently approved anti-TNF agent, limited numbers of patients receiving this drug have 
been collected to date, preventing analyses in this subgroup. As adalimumab is increasingly 
being prescribed, the continued recruitment of patients should increase the size of this subgroup.  
 
Lastly, the serology has been measured cross-sectionally at the time of sample collection, which 
may be some time after commencement of treatment. Previous studies have shown that although 
titres are affected by treatment, status is not (7;25). Hence, in all the analyses, auto-antibody 
status rather than titre has been used and this may have resulted in loss of power. It should be 
noted that the proportion of RF positive patients in the current study is higher than that reported 
previously for the BSRBR cohort as a whole (89% vs. 72%, respectively) (5). This is most likely 
to be due to differences in data collection methods: the BSRBR study relies on information 
collected from contributing physicians whereas, for the purposes of the current study, RF was re-
measured in all patients for whom a serum sample was available. 
 
Conversely, our study has several advantages over previous investigations. Importantly, the use 
of the BSRBR to identify suitable patients has meant that the subgroup studied is representative 
of the BSRBR in its entirety. As, until relatively recently, almost all patients receiving an anti-
TNF drug in the UK for RA were included on this register, the cohort studied is likely to reflect 
the characteristics of anti-TNF-treated patients as a whole, at least in the UK. Furthermore, a 
wealth of clinical and demographic data had already been collected, creating a well characterised 
cohort. In addition, this is the largest collection of such patients, to date, allowing robust 
inferences to be drawn. Finally, the use of the DAS28 measure rather than the EULAR response 
criteria enhances the power of the study to detect association with genetic predictors of response. 
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The results of the current study confirm findings of smaller studies in which similar trends 
between drug response and both baseline RF and anti-CCP antibody titres have been 
demonstrated (3;4;7). As discussed by Alessandri et al, RF and anti-CCP antibodies are 
independent markers of disease severity for RA (26). Thus the present findings could be 
interpreted as showing that those patients with the most severe disease are least likely to respond 
to these therapies. Indeed, there is some evidence to support this hypothesis, as HAQ score, a 
measure of disability, was also significantly associated with response. However, the association 
between the autoantibodies and treatment response persisted even after adjustment for the HAQ 
score suggesting a more complex relationship. Indeed, carriage of SE alleles, previously shown 
to be associated with disease severity, showed no association with improvement in the DAS28 
score.  
 
A number of clinical markers of anti-TNF treatment response have previously been identified 
including concurrent DMARD therapy, baseline HAQ and gender (3-5). The current study has 
confirmed that the presence of RF and anti-CCP antibodies can be added to that list but, even 
when all these factors are combined, only a small proportion of the variance in drug response 
(R2=17%) is accounted for. Currently, therefore, a model including these variables will not be 
useful in the clinical setting. We hypothesize that, in addition to these clinical and serological 
factors, psychological and genetic factors will play a role and the challenge now is to identify 
these. No association was observed between treatment response and carriage of the RA 
susceptibility allele of the PTPN22 gene and, in keeping with most previous studies, no 
association of treatment response was observed with SE carriage, a well-established RA severity 
and susceptibility locus. It is, perhaps, not surprising that genes contributing to disease 
susceptibility are different to those that determine response to treatment, but large studies of 
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well-characterised patient cohorts will be required to identify the multiple genes that are likely 
contribute, each with modest effects, to treatment response. 
 
In summary, the presence of RF or anti-CCP antibodies was associated with a reduced response 
to anti-TNF drugs as a whole and infliximab, in particular. However, the presence of these 
antibodies only accounts for a small proportion of the variance in treatment response. It is likely 
that genetic factors will contribute to determining the response to treatment with these agents but 
do not include the 2 genes known to confer susceptibility to RA. 
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Appendix: Members of the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate 
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Baseline characteristics Etanercept Infliximab Adalimumab Combined 
Number of cases 278 (43) 296 (46) 68 (11) 642 
Age (years)* 57 (11) 58 (11) 59 (12) 57 (11) 
Female 223 (80) 228 (77) 51 (75) 502 (78) 
Current smokers 56 (20) 51 (17) 6 (9) 113 (18) 
Ever smoked 163 (59) 168 (57) 35 (51) 366 (57) 
Disease duration (years)* 13 (9) 15 (10) 13 (10) 14 (10) 
DAS28* 6.7 (1) 6.7 (1) 6.5 (1) 6.7 (1) 
HAQ* 2 (0.6) 2 (0.6) 2 (0.5) 2 (0.6) 
Concurrent DMARD(s) 152 (55) 277 (94) 38 (56) 467 (73) 
Concurrent steroids 105 (38) 135 (46) 24 (35) 264 (41) 
Previous biologic 21 (8) 10 (3) 3 (4) 34 (5) 
Table 1. Baseline characteristics 
Values are n (%) or mean (SD)* 
 
 
 Etanercept Infliximab Adalimumab Combined 
RF positive 219/241 (91) 189/218 (87) 54/62 (87) 462/521 (89) 
Anti-CCP positive 206/241 (86) 177/218 (81) 42/62 (68) 425/521 (82) 
SE carriage 184/225 (82) 208/261 (80) 40/49 (82) 432/535 (81) 
PTPN22 carriage 78/268 (29) 93/287 (33) 17/64 (27) 188/619 (30) 
Table 2. RF, anti-CCP, SE and PTPN22 status 
Values are n of positive/total available (% positive) 
 
 
  Mean DAS Score* (SD) Linear regression, Coef. (95% CI) p-value 
Predictor n* (%) Base Improvement Adjusted 1† Adjusted 2‡ 
RF -ve 59 (11) 6.72 (1) 3.03 (1.7) ref ref 
RF +ve 462 (89) 6.59 (1) 2.43 (1.5) -0.48 (-0.87, -0.08) p=0.02 -0.48 (-0.89, -0.07) p=0.02 
Anti-CCP -ve 96 (18) 6.61 (1) 2.90 (1.6) ref ref 
Anti-CCP +ve 425 (82) 6.61 (1) 2.40 (1.5) -0.39 (-0.71, -0.07) p=0.02 -0.39 (-0.72, -0.06) p=0.02 
SE -ve 103 (19) 6.65 (1) 2.38 (1.5) ref ref 
SE +ve 432 (81) 6.71 (1) 2.49 (1.5) 0.07 (-0.25, 0.39) p=0.68 0.06 (-0.26, 0.39) p=0.70 
PTPN22 -ve 431 (70) 6.67 (1) 2.51 (1.6) ref ref 
PTPN22 +ve 188 (30) 6.72 (1) 2.48 (1.4) -0.11 (-0.36, 0.15) p=0.41 -0.13 (-0.39, 0.13) p=0.34 
Table 3. Linear regression for RF, anti-CCP, SE and PTPN22 
*Figures represent those across complete subgroup of 642 patients. †Initial analyses were performed across the 
entire cohort, djusting for baseline DAS28, HAQ, concurrent DMARD therapy and gender. ‡Subsequent analyses 
excluded patients with previous exposure to a biologic agent. SD = standard deviation, Coef. = coefficient, CI = 
confidence interval, ref = reference group.  
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  Mean DAS Score* (SD) Linear regression Coef. (95% CI) p-value 
Predictor n* (%) Base Improvement Adjusted† Difference between drugs 
etanercept     
ref RF –ve 22 (9) 6.63 (1) 2.69 (1.8) ref 
RF +ve 219 (91) 6.63 (1) 2.43 (1.5) -0.25 (-0.89, 0.39) p=0.44 
infliximab     
-0.58 (-1.4, 0.03) 
p=0.18 RF –ve 29 (13) 6.79 (1) 3.34 (1.6) ref RF +ve 189 (87) 6.60 (1) 2.34 (1.6) -0.83 (-1.40, -0.27) p=0.004 
etanercept     
ref Anti-CCP -ve 35 (15) 6.62 (1) 2.72 (1.4) ref 
Anti-CCP +ve 206 (85) 6.64 (1) 2.40 (1.5) -0.26 (-0.77, 0.26) p=0.33 
infliximab     -0.41 (-1.1, 0.3) 
p=0.26 Anti-CCP -ve 41 (19) 6.62 (1) 3.07 (1.7) ref 
Anti-CCP +ve 177 (81) 6.63 (1) 2.33 (1.6) -0.67 (-1.16, -0.18) p=0.007 
Table 4. Linear regression of RF and anti-CCP, stratifying for anti-TNF agents 
*Figures represent those across complete subgroup of 642 patients. †Analyses adjusted for baseline DAS28, HAQ, 
concurrent DMARD therapy and gender. SD = standard deviation, Coef. = coefficient, CI = confidence interval, ref 
= reference group.  
 
